Press Release: Tolebrutinib meets primary endpoint in HERCULES ... - Sanofi
WEBSep 2, 2005 · Positive results from the HERCULES phase 3 study showed that tolebrutinib, Sanofi’s oral brain-penetrant BTK inhibitor, met the primary endpoint of improvement over placebo in delaying time to onset of confirmed disability progression (CDP) in people with non-relapsing secondary progressive MS (nrSPMS).
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB3 days ago · FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB3 days ago · Sanofi’s safety and tolerability analysis showed 4.1% of people on tolebrutinib had liver enzyme levels of at least three times the upper limit of normal, compared to 1.6% of the patients taking ...
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
WEBFeb 23, 2022 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
Tolebrutinib clinical trial program update - Sanofi
WEBAug 8, 2022 · The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain unchanged with submission in relapsing MS expected in 2024.
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
WEBSep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis. Houman Ashrafian, MD, PhD. Sanofi has announced topline data from its phase 3 HERCULES study (NCT04411641) of its ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB3 days ago · Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS),. The results from the HERCULES Phase III trial (NCT04411641) showed that Bruton tyrosine kinase (BTK) inhibitor delayed the time to six-month disability progression by 31% compared to placebo.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
WEB3 days ago · Sanofi revealed the top-line result from HERCULES a few weeks ago, noting that tolebrutinib is the only drug in the oral BTK inhibitor class to have shown an improvement in disability progression ...
Sanofi's Tolebrutinib Delays Disability Progression In Patients …
WEB3 days ago · Friday, Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that ...
Press Room - Sanofi US News
WEBFeb 24, 2022 · Tolebrutinib is an investigational brain-penetrant Bruton’s tyrosine kinase inhibitor that achieves CSF concentrations needed for targeting B lymphocytes and microglial cells.
Skip to content